<DOC>
	<DOC>NCT00903838</DOC>
	<brief_summary>This is a multicenter, randomized, double blind, pramipexole-controlled parallel group study of pardoprunox as adjunctive treatment to levodopa.</brief_summary>
	<brief_title>A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.</brief_title>
	<detailed_description>Approximately 44 patients are to be randomized in a 3:1 ratio to two possible treatment groups, pardoprunox and pramipexole, respectively. The first part of the study will be blinded and consists of a minimum 1-week screening period, a 4-week switch and stabilization period and an 8-week maintenance period. The second part of the study will be open label pardoprunox treatment with a dose adjustment period of 4 weeks followed by long term maintenance treatment.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion Criteria Patients who have signed informed consent Diagnosis of idiopathic Parkinson's Disease Stable treatment with Ldopa and dopamine agonist for at least 28 days prior to randomization Presence of a recognizable ON and OFF state (motor fluctuations) Minimum hours of OFFtime per day of 1.5 hours (during waking hours including early morning akinesia) as recorded per baseline diaries Minimum hours of ON time with troublesome dyskinesia of 2 hours (during waking hours) as recorded per baseline diaries Prevalent expression of severely disabling dyskinesias during the waking day, i.e. dyskinesias are present at least 25% of the waking hours (UPDRS Part 4 item 32 &gt;= 2) in combination with a degree of disability which is moderate or higher (UPDRS Part 4 item 33 &gt;=2) Exclusion Criteria Diagnosis is unclear or a suspicion of other parkinsonian syndromes Patients who have undergone surgery for the treatment of PD</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Parkinson's disease</keyword>
</DOC>